[Direct oral anticoagulation and XXXX : Interventional therapy management].

@entity1 @entity8 @entity548 @entity2067 @entity30971 @entity1031 @entity5424 @entity360 @entity1229
BACKGROUND: More and more @entity1 are being treated with direct oral anticoagulants (DOAC). Under treatment with DOACs @entity360 appears to occur more frequently, particularly in the lower gastrointestinal tract, compared to treatment with @entity2067 antagonists (e.g. @entity1229 ). OBJECTIVE: A possible approach should now be elaborated in a joint effort by gastroenterologists and cardiologists. MATERIAL AND METHODS: A selective literatue search was carried out and own experiences were also included. RESULTS: The decision to perform procoagulant therapy by slowly injecting 30-50  IU prothrombin complex concentrate ( @entity30971 ) per kg body weight intravenously depends on various factors and should be assessed critically. Specific antidotes are awaiting approval. After a @entity548 episode potentially controllable and reversible triggers must be excluded (e.g. drug interactions and @entity8 ). The risk of recurrent @entity548 and the risk of @entity1031 events have to be weighed against each other before deciding to readminister an anticoagulant and its form. Dose reduction and changing to @entity5424 (in reduced dosage) are options for risk reduction and @entity2067 antagonists can also be considered. DISCUSSION: It is still unclear what role specific antidotes will play.
